Near-term momentum pushes Monopar Therapeutics stock up 7.19%

Traders Union
All News
Financial News
Monopar Therapeutics rises 7.19% today

Highlights

MNPR/USD is exhibiting a strong bullish trend, trading above short-, medium-, and long-term moving averages.
Momentum and oscillator indicators signal buyer dominance and overbought conditions, with intraday price action reaching a high of $73.61.
For the next 2–3 days, projected range is $68.84 to $77.07, with a high probability of holding or breaking above this range.

Overbought conditions and buyer strength drive momentum signals

On the hourly chart, price remains above the MA-20 at $67.09 and MA-50 at $63.23, while on the daily chart, MNPR trades above the MA-200 at $66.78. The Ichimoku Kijun level at $65.98 provides immediate support. Momentum indicators, including MACD and ADX, remain in Buy mode. Overbought readings are seen in the RSI (72.34), Stoch RSI (Strong Buy), and CCI, while the Bull/Bear Power (BBP) is also overbought and indicates persistent buyer dominance intraday. The Awesome Oscillator is neutral and does not confirm the prevailing upward momentum.

High probability bullish outlook as volatility shapes short-term range

For the next 2–3 trading days, the expected trading range for MNPR is $68.84 to $77.07, defining the typical volatility band relative to current levels. The probability of an upward move is very high, while a downside scenario remains unlikely. A break above $77.07 could open further upside, whereas a decline below $68.84 would suggest a short-term bearish reversal.

Viktoras Karapetjanc, analyst at Traders Union, sees strong bullish momentum in Monopar Therapeutics (MNPR) as it trades firmly above key moving averages. He notes that overbought signals and persistently high buyer interest point to an extension of the current uptrend. The expert believes the lack of news flow reduces short-term uncertainty and lets technical factors dominate. "With current levels well-supported and momentum in our favor, I am confident that MNPR has a high probability of further gains in the coming days as long as it holds above $68.84."

Earlier, analysts noted that Monopar Therapeutics was demonstrating upside momentum supported by bullish technical signals, while cautioning about strong overbought conditions. The latest session reinforces this view, but with volatility and overbought levels rising further, traders should focus on the potential for a breakout above $77.07 as the next catalyst for continued gains.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.